Skip to main content
Top
Published in: International Journal of Hematology 5/2015

01-11-2015 | Case Report

Identification of the SOX5 gene as a novel IGH-involved translocation partner in BCL2-negative follicular lymphoma with t(12;14)(p12.2;q32)

Authors: Masayuki Shiseki, Akihiro Masuda, Kentaro Yoshinaga, Naoki Mori, Michiko Okada, Toshiko Motoji, Junji Tanaka

Published in: International Journal of Hematology | Issue 5/2015

Login to get access

Abstract

Chromosome translocations involving the immunoglobulin heavy chain (IGH) gene locus at chromosome region 14q32 are often observed in B-cell lymphoid neoplasms. Of these, t(14;18)(q32;q21) results in juxtaposition of the IGH gene on chromosome 14 and the BCL2 gene on chromosome 18, leading to the overexpression of BCL2 anti-apoptotic protein, which plays a critical role in the development of follicular lymphoma (FL). However, BCL2 overexpression is not observed in approximately 10 % of FL, and the molecular pathogenesis of BCL2-negative FL has not been elucidated. Here, we identify the SRY-related high-morbidity-group (HMG) box 5 (SOX5) gene on chromosome 12p12 as a novel IGH-involved translocation partner in the case of BCL2-negative follicular lymphoma (FL) with a complex karyotype including t(12;14)(p12.2;q32) by long-distance inverse PCR. As a result of this translocation, the SOX5 gene is juxtaposed to the enhancer of the IGH gene; SOX5 overexpression in neoplastic cells was demonstrated by immunohistochemistry. The results of the present study suggest a role for SOX5 in the molecular pathogenesis of FL.
Literature
1.
go back to reference Skinnder BF, Horsman DE, Dupuis B, Gascoyne RD. Bcl-6 and bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Human Pathol. 1999;30:803–8.CrossRef Skinnder BF, Horsman DE, Dupuis B, Gascoyne RD. Bcl-6 and bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Human Pathol. 1999;30:803–8.CrossRef
2.
go back to reference Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E 3rd, et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest. 2004;84:235–44.CrossRefPubMed Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E 3rd, et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest. 2004;84:235–44.CrossRefPubMed
3.
go back to reference Karube K, Guo Y, Suzumiya J, Sugita Y, Nomura Y, Yamamoto K, et al. CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood. 2007;109:3076–9.PubMed Karube K, Guo Y, Suzumiya J, Sugita Y, Nomura Y, Yamamoto K, et al. CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood. 2007;109:3076–9.PubMed
4.
go back to reference Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009;114:826–34.PubMedCentralCrossRefPubMed Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009;114:826–34.PubMedCentralCrossRefPubMed
5.
go back to reference Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne RD, et al. MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood. 2011;118:5550–8.PubMedCentralCrossRefPubMed Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne RD, et al. MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood. 2011;118:5550–8.PubMedCentralCrossRefPubMed
6.
go back to reference Shiseki M, Kitagawa Y, Wang YH, Yoshinaga K, Kondo T, Kuroiwa H, et al. Lack of nucleophosmin gene mutations in myeloid malignaincies with chromosome 5 abnoralities. Leuk Lymphoma. 2007;48:2141–4.CrossRefPubMed Shiseki M, Kitagawa Y, Wang YH, Yoshinaga K, Kondo T, Kuroiwa H, et al. Lack of nucleophosmin gene mutations in myeloid malignaincies with chromosome 5 abnoralities. Leuk Lymphoma. 2007;48:2141–4.CrossRefPubMed
7.
go back to reference Willis TG, Jadayel DM, Coignet LJA, Abdul-Rauf M, Treleaven JG, Catovsky D, et al. Rapid molecular cloning of rearrangement of the IGHJ locus using long-distance inverse polymerase chain reaction. Blood. 1997;90:2456–64.PubMed Willis TG, Jadayel DM, Coignet LJA, Abdul-Rauf M, Treleaven JG, Catovsky D, et al. Rapid molecular cloning of rearrangement of the IGHJ locus using long-distance inverse polymerase chain reaction. Blood. 1997;90:2456–64.PubMed
8.
go back to reference Okada M, Suto Y, Hirai M, Shiseki M, Usami A, Okajima K, et al. Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies. Cancer Genet. 2012;205:18–24.CrossRefPubMed Okada M, Suto Y, Hirai M, Shiseki M, Usami A, Okajima K, et al. Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies. Cancer Genet. 2012;205:18–24.CrossRefPubMed
9.
go back to reference Wunderle VM, Critcher R, Ashworth A. Good fellow PN. Cloning and characterization of SOX5, a new member of the human SOX gene family. Genomics. 1996;36:354–8.CrossRefPubMed Wunderle VM, Critcher R, Ashworth A. Good fellow PN. Cloning and characterization of SOX5, a new member of the human SOX gene family. Genomics. 1996;36:354–8.CrossRefPubMed
10.
go back to reference Lefebvre V, Dumitriu B, Penzo Mendez A, Han Y, Pallavi B. Control of cell fate and differentiation by sry-related high-morbidity-group box (Sox) transcriptional factors. Int J Biochem Cell Biol. 2007;39:2195–214.PubMedCentralCrossRefPubMed Lefebvre V, Dumitriu B, Penzo Mendez A, Han Y, Pallavi B. Control of cell fate and differentiation by sry-related high-morbidity-group box (Sox) transcriptional factors. Int J Biochem Cell Biol. 2007;39:2195–214.PubMedCentralCrossRefPubMed
11.
go back to reference Ueda R, Yoshida K, Kawase T, Kawakami Y, Toda M. Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. Int J Cancer. 2007;120:1704–11.CrossRefPubMed Ueda R, Yoshida K, Kawase T, Kawakami Y, Toda M. Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. Int J Cancer. 2007;120:1704–11.CrossRefPubMed
12.
go back to reference Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y, et al. Transcriptional factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol. 2008;214:445–55.CrossRefPubMed Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y, et al. Transcriptional factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol. 2008;214:445–55.CrossRefPubMed
13.
go back to reference Ma S, Chan YP, Woolcock B, Hu L, Wong KY, Ling MT, et al. DNA fingerprinting tags novel altered chromosomal regions and identifies the involvement of SOX5 in the progression of prostate cancer. Int J Cancer. 2009;124:2323–32.CrossRefPubMed Ma S, Chan YP, Woolcock B, Hu L, Wong KY, Ling MT, et al. DNA fingerprinting tags novel altered chromosomal regions and identifies the involvement of SOX5 in the progression of prostate cancer. Int J Cancer. 2009;124:2323–32.CrossRefPubMed
14.
go back to reference Harris ML, Baxter LL, Loftus SK, Pavan WJ. Sox proteins in melanocyte development and melanoma. Pigment Cell Melanoma Res. 2011;23:496–513.CrossRef Harris ML, Baxter LL, Loftus SK, Pavan WJ. Sox proteins in melanocyte development and melanoma. Pigment Cell Melanoma Res. 2011;23:496–513.CrossRef
15.
go back to reference Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics. 2008;1:13–29.PubMedCentralCrossRefPubMed Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics. 2008;1:13–29.PubMedCentralCrossRefPubMed
16.
go back to reference Ehrhardt GRA, Hijikata A, Kitamura H, Ohara O, Wang J-Y, Cooper MD. Discriminating gene expression profiles of memory B cell subpopulation. J Exp Med. 2008;205:1807–17.PubMedCentralCrossRefPubMed Ehrhardt GRA, Hijikata A, Kitamura H, Ohara O, Wang J-Y, Cooper MD. Discriminating gene expression profiles of memory B cell subpopulation. J Exp Med. 2008;205:1807–17.PubMedCentralCrossRefPubMed
17.
go back to reference Charles ED, Brunetti C, Marukian S, Ritola KD, Talal AH, Marks K, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood. 2011;117:5425–37.PubMedCentralCrossRefPubMed Charles ED, Brunetti C, Marukian S, Ritola KD, Talal AH, Marks K, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood. 2011;117:5425–37.PubMedCentralCrossRefPubMed
18.
go back to reference Moore CR, Edwards SKE, Xie P. Targeting TRAF3 downstream signaling pathways in B-cell neoplasms. J Cancer Sci Ther. 2015;7:67–74.PubMedCentralPubMed Moore CR, Edwards SKE, Xie P. Targeting TRAF3 downstream signaling pathways in B-cell neoplasms. J Cancer Sci Ther. 2015;7:67–74.PubMedCentralPubMed
19.
go back to reference Storlazzi CT, Albano F, Lo Cunsolo C, Doglioni C, Guastadisegni MC, Impera L, et al. Upregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic lymphoma. Leukemia. 2007;21:2221–5.CrossRefPubMed Storlazzi CT, Albano F, Lo Cunsolo C, Doglioni C, Guastadisegni MC, Impera L, et al. Upregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic lymphoma. Leukemia. 2007;21:2221–5.CrossRefPubMed
20.
go back to reference Zafarana G, Gilles AJM, van Gurp RJHLM, Olsson PG, Elstrodt F, Stoop H, et al. Coamplification of DAD-R, SOX5, and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestation. Cancer Res. 2002;62:1822–31.PubMed Zafarana G, Gilles AJM, van Gurp RJHLM, Olsson PG, Elstrodt F, Stoop H, et al. Coamplification of DAD-R, SOX5, and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestation. Cancer Res. 2002;62:1822–31.PubMed
21.
go back to reference Cheung KJJ, Delaney A, Ben-Neriah S, Schein J, Lee T, Shah SP, et al. High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer. 2010;49:669–81.CrossRefPubMed Cheung KJJ, Delaney A, Ben-Neriah S, Schein J, Lee T, Shah SP, et al. High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer. 2010;49:669–81.CrossRefPubMed
Metadata
Title
Identification of the SOX5 gene as a novel IGH-involved translocation partner in BCL2-negative follicular lymphoma with t(12;14)(p12.2;q32)
Authors
Masayuki Shiseki
Akihiro Masuda
Kentaro Yoshinaga
Naoki Mori
Michiko Okada
Toshiko Motoji
Junji Tanaka
Publication date
01-11-2015
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2015
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1823-z

Other articles of this Issue 5/2015

International Journal of Hematology 5/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine